- Germany
- /
- Specialty Stores
- /
- XTRA:MRX
Mister Spex Second Quarter 2025 Earnings: €0.15 loss per share (vs €0.22 loss in 2Q 2024)
Mister Spex (ETR:MRX) Second Quarter 2025 Results
Key Financial Results
- Revenue: €54.1m (down 21% from 2Q 2024).
- Net loss: €4.82m (loss narrowed by 36% from 2Q 2024).
- €0.15 loss per share (improved from €0.22 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mister Spex Earnings Insights
Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Specialty Retail industry in Germany.
Performance of the German Specialty Retail industry.
The company's shares are down 2.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Mister Spex you should be aware of, and 1 of them is potentially serious.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:MRX
Mister Spex
Mister Spex SE retails optical products in Germany and internationally.
Excellent balance sheet and slightly overvalued.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives

Making sense of 1.75 trillion IPO
SpaceX? Only Fast in - Fast out!

INDIAN OIL CORPORATION IS THE TITAN IN TRANSITION
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
